報價延遲最少15分鐘:2025/08/16 04:24 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.33 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.33/1.11
|
|
企業價值
4.18B
|
| 資產負債 |
|
每股賬面淨值
4.87
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
957.80M
|
|
每股收益
3.75
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/16 04:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
